On July 16, Americans for Ingredient Transparency (AFIT) — the Washington coalition that lists Nestlé, PepsiCo, Coca-Cola, Keurig Dr Pepper, General Mills, Kraft Heinz, Conagra Brands and Tyson Foods on its member roster — filed a $170,000 lobbying disclosure for Q2 2026. That matches its Q1 spend, runs 17x above the $10,000 it reported in Q3 2025, and is dwarfed by what individual members pay directly. The bill it is trying to write, the FRESH and Affordable Foods Act, would preempt the patchwork of state food-additive bans now advancing in California, New York and Nebraska. The strategy is not transparency for its own sake; it is a single federal label architecture that lets the largest CPGs reformulate once and sell everywhere.
What the lobby actually bought
AFIT's $170,000 Quarter Is the Tip of a Much Bigger Spend
- AFIT itself ramped from $10,000 in Q3 2025 to $170,000 in Q1 2026 and $170,000 in Q2 2026, a 17x increase in nine months, filed through the Russell Group (legislative registration date Oct 3, 2025).
- Separate lobbying on FDA GRAS reform by trade associations and companies nearly tripled in Q1 2026 versus Q1 2025, per NOTUS analysis of LDA filings.
- Four of the AFIT members — Nestlé, PepsiCo, Coca-Cola and Keurig Dr Pepper — met directly with FDA officials on GRAS reform in 2026, per federal meeting records reviewed by NOTUS.
- Conagra Brands alone reported $480,000 in federal lobbying in 2024 (Opensecrets), separate from and additive to the AFIT pass-through.
The legislative vehicle
Two Bills, One Goal: Replace 50 State Regimes With One Federal Label
The federal vehicle has changed once and is changing again. Sen. Roger Marshall's Better Food Disclosure Act of 2025 originally contained a preemption clause that would have nullified state food-additive bans; Marshall removed that section in November 2025 after MAHA-aligned voters revolted. AFIT and the Consumer Brands Association then backed a successor: the FRESH and Affordable Foods Act, a draft bill introduced by Rep. Kat Cammack (R-FL) and headed for a House Energy & Commerce health subcommittee hearing. The new text again narrows GRAS self-determination but, crucially, retroactively approves prior GRAS determinations and preempts state action.
| Bill | Sponsor | Preemption? | Status |
|---|---|---|---|
| Better Food Disclosure Act of 2025 | Sen. Roger Marshall (R-KS) | Yes — preemption clause removed Nov 2025 | Reported out without preemption |
| FRESH and Affordable Foods Act | Rep. Kat Cammack (R-FL) | Yes — would preempt state additive laws | Draft bill; House E&C health subcommittee hearing set |
Why now
The State Patchwork Is Forcing Eight Reformulations, Eight Different Labels
- California AB 418 bans brominated vegetable oil, potassium bromate, propylparaben and Red No. 3 from Jan 1, 2027.
- Nebraska LB 940, signed April 14, 2026, prohibits Blue 1, Blue 2, Green 3, Red 40 and other dyes.
- California AB 660, effective July 1, 2026, standardizes date labels and bans 'Sell By' on consumer packaging.
- A February 2026 Policy Navigation Group study (commissioned by industry) concluded that recent state disclosure laws impose substantial reformulation costs — the economic pretext AFIT cites for federal preemption.
The economic stakes
Federal Preemption Resets a ~$260B Reformulation Bill to a Single One-Time Cost
AFIT members spent decades on GRAS self-determination — the practice of declaring an ingredient safe without notifying FDA. Closing the GRAS loophole would impose real reformulation costs; industry estimates cluster around $50–100M per major additive per state regime. The total cost of complying with the current state patchwork — Red No. 3 bans in CA, dye bans in NE, additive bans in NY — runs into the hundreds of millions for a portfolio the size of Kraft Heinz or General Mills. A federal preemption that grandfather's existing GRAS determinations resets that bill to a single, predictable reformulation cycle.
AFIT coalition member FY2025 revenue and gross margin
Revenue scale (USD) and gross margin — the bigger the margin gap to peers, the bigger the savings from a single reformulation
Unit: USD billions
PepsiCo
GM 54.1%
93.9
Nestlé
GM 45.6% (CHF)
85.5
Coca-Cola
GM 61.6%
47.9
Tyson Foods
GM 6.5%
54.4
Kraft Heinz
GM 33.3%
24.9
General Mills
GM 33.5%
18.4
Keurig Dr Pepper
GM 54.2%
16.6
Conagra Brands
GM 23.9%
11.3
The companies with the most SKUs and the thinnest margins — Conagra Brands at 23.9% gross margin and Kraft Heinz at 33.3% — face the largest reformulation-to-revenue ratio. A federal preemption that locks in existing GRAS determinations converts that exposure into a one-time capex line; without it, every state enaction ratchets the bill higher.
The first casualty
Conagra's 50% Dividend Cut Is the Bellwether No One on Capitol Hill Can Ignore
On July 15, 2026 — eight days before the AFIT disclosure — Conagra Brands cut its annual dividend from $1.40 to $0.70 (a 50% reduction), took a $2B impairment charge, and guided FY2027 organic sales down 1–3%. The same release replaced long-time CEO Sean Connolly with a new chief executive, citing 'rising inflation and weakening sales' as the proximate cause. Conagra runs 23.9% gross margin against Keurig Dr Pepper's 54.2% and Coca-Cola's 61.6%; it has the least cushion in the AFIT coalition to absorb state-by-state reformulation.
CAG dividend cut
50%
$1.40 → $0.70 annual, Jul 15 2026
CAG impairment charge
$2.0B
Q4 FY2026
CAG FY2027 sales guide
-1% to -3%
Organic net sales vs -0.4% in FY2026
CAG gross margin
23.9%
Lowest in AFIT cohort (FY2026)
Why this is structural, not tactical
The MAHA Coalition Killed the Senate Version. The House Bill Is the Backup Plan.
The AFIT playbook survived a near-death experience. Sen. Marshall dropped the preemption clause from the Better Food Disclosure Act in November 2025 after MAHA-aligned voters objected. AFIT and the Consumer Brands Association responded by backing the Cammack draft in April 2026, which is now scheduled for a House Energy & Commerce health subcommittee hearing — the first congressional food-additive hearing in years. The bill's text is undisclosed in detail but is reported to narrow GRAS self-determination, retroactively bless prior GRAS determinations, and preempt state food-additive laws. In other words, the same three policy levers Marshall dropped, repackaged.
- Short-term (0–6 months): House subcommittee hearing on the FRESH Act. Cammack bill either advances or dies on committee schedule.
- Short-term (6–12 months): California AB 418 (Red No. 3 ban) and Nebraska LB 940 (dye bans) take effect, adding ~$200M+ of incremental reformulation costs to each AFIT member — exact amount undisclosed but cited by industry-funded Policy Navigation Group study.
- Long-term (1–3 years): If federal preemption passes, AFIT members refinance the state-patchwork reformulation bill into a single SKU cycle. If it fails, the patchwork compounds and a second dividend cut at a thin-margin AFIT member is a non-trivial tail risk.
Cross-supply-chain
Upstream and Downstream: Who Sits Beside the Big Eight
Upstream: AFIT's preemption push directly insulates colorant and additive suppliers — Sensient Technologies, International Flavors & Fragrants (now IFF), and privately held ingredient houses whose portfolios include Red 40, Blue 1 and the brominated compounds now being banned state by state. A federal preemption locks in their existing GRAS determinations and protects billions in embedded reformulation capex they have already made. Downstream: private-label manufacturers (TreeHouse Foods, premium private label at retailers) are exposed in the opposite direction — a federal preemption that freezes the status quo preserves brand-name pricing power against private-label share gains built on 'clean label' positioning.
- Upstream — colorant/additive suppliers: a federal GRAS grandfather clause protects their installed reformulation base; disclosed GRAS self-determination revenue lines vary, with no single company named in AFIT filings.
- Upstream — packaging and label printers: a federal single-label regime is unambiguously positive; Multi-Color Corporation (now part of Platinum Equity) and CCL Industries handle most CPG label runs and would see a 1x capex reset rather than 50x.
- Downstream — retailers: Kroger, Walmart and Costco have made 'clean label' private-label commitments that AFIT preemption would partially undermine; disclosure on retail exposure not provided.
- Downstream — GLP-1-aligned food brands: Nestlé's own Vital Pursuit has been marketed to GLP-1 users; AFIT's 'uniform science-and-risk-based standard' messaging is consistent with positioning GLP-1-friendly SKUs as medically distinct, not reformulation targets.
Investment synthesis
Where the Catalyst Lands in 2026
AFIT's $170,000 Q2 2026 disclosure is the most measurable artifact of a much larger corporate push. The numbers the article leans on are: the 17x ramp in AFIT spending since Q3 2025, the 50% dividend cut at Conagra Brands, the 23.9% gross margin that makes CAG the most exposed member, and the legislative arc from Marshall's dropped preemption to Cammack's pending FRESH Act. The investable takeaway: federal preemption is binary in 2026 (House subcommittee hearing), but the state patchwork is a slow-moving liability that compounds with every bill signed. CPGs that already run pricing power (Coca-Cola, Keurig Dr Pepper, PepsiCo) absorb the cost; CPGs that don't (Conagra Brands, Kraft Heinz) re-price or cut capital returns.
Stocks exposed to the AFIT federal-label thesis
- Just cut its dividend 50% (Jul 15, 2026) and took a $2.0B impairment — a 23.9% gross-margin CPG in an AFIT coalition cannot absorb 50-state reformulation without a federal preemption win.
- Guided FY2027 organic sales down 1–3% on July 15; the state additive patchwork (CA AB 418, NE LB 940) adds reformulation cost to that base in 2026–2027.
- Federal preemption passing = single SKU reformulation cycle and a 2027–2028 margin reset; federal preemption failing = a second dividend cut is the tail risk.
- Sits at the top of the AFIT coalition alongside PEP, KO and KDP; FY2025 revenue CHF 85.5B at 45.6% GM gives it the scale to convert a federal preemption into a single reformulation capex event.
- Voluntarily removing FD&C colors by mid-2026 (announced June 25, 2025) is the visible 'clean label' capex that a federal preemption would protect from state-by-state re-papering.
- Vital Pursuit GLP-1 line is the most exposed to a 'science-and-risk-based' federal label; AFIT lobbying positions Nestlé as the regulator's preferred partner, not the target.
- Board-confirmed split into two public companies (announced September 2, 2025) means the federal-label thesis gets priced twice — once into the grocery unit, once into the away-from-home unit.
- FY2025 revenue $24.9B at 33.3% GM and a $5.85B net loss make it the second-most-exposed thin-margin AFIT member; a federal preemption that locks in GRAS is the difference between 2027 capex discipline and another impairment round.
- MAHA-aligned voter sentiment in 2026 is the binding constraint: even if Cammack's FRESH Act clears committee, the Senate floor remains a hostile environment for federal preemption of state additive laws.
- FY2026 revenue $18.4B at 33.5% GM — exposure profile sits between CAG (worst) and PEP (best); the federal-label outcome is a meaningful but not existential margin lever.
- AFIT coalition membership gives GIS a seat at the federal preemption table, but the company's prior 'clean label' voluntary commitments limit the upside from a status-quo GRAS lock.
- FY2026 net income turned negative (TTM -$87.6M) — the company is already absorbing reformulation cost; federal preemption would convert a 2027 cash drain into a 2027 capex line.
- Met FDA officials directly on GRAS reform alongside Nestlé, PepsiCo and Coca-Cola (per NOTUS review of federal meeting records, June 2026).
- FY2025 revenue $16.6B at 54.2% GM — the highest gross margin in the AFIT cohort, meaning every dollar of reformulation cost is the smallest percentage drag on operating income.
- The K-Cup and single-serve platform is the cleanest preemption beneficiary: a federal label architecture means one SKU change ships across all 50 states, not fifty.
- FY2025 revenue $93.9B at 54.1% GM; the largest AFIT member by sales, but the Frito-Lay snacks portfolio is the most exposed to state-by-state dye and additive bans.
- Already in the FDA GRAS meetings; AFIT preemption is the most cost-effective single reformulation cycle in PepsiCo's history.
- Pricing-power offset: PEP's GLP-1-disclosed snacks and 'Simply' portfolio create an internal hedge against a federal preemption that fails.
